Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 28, 2026
Cabaletta Bio, Inc. (CABA)
A forensic read on Cabaletta Bio, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Clean
Earnings quality
2
Forensic signals
-131.6%
ROE
$496M
Market cap
Cabaletta Bio, Inc. earns a C (Mixed — selective) forensic quality grade. 2 forensic signals were flagged in its latest SEC filings, led by accruals ratio.
What the filings flag
+466.6%Accruals ratio. Net operating assets grew +466.6% relative to their average in FY2025 — the accrual component of earnings. Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The cash-flow cross-check agrees: reported earnings ran behind operating cash by -422% of net operating assets.
-426%Return on invested capital. Return on invested capital is -426% and slipping from -329% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
Key fundamentals
Free Cash Flow$-132.3M
Return on Equity-149.8%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Cabaletta Bio, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about CABA's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown
🔒Peer comparison + filing-change monitoring & alerts
No credit card · informational only, not investment advice · see the track record
← Browse all forensic stock analyses
Data from SEC EDGAR public filings · metrics as of Jun 28, 2026. Forensic signals flag probability, not certainty.